Antiretroviral drug resistance testing in adults infected with human immunodefidency virus type 1: 2003 Recommendations of an International Aids Society-USA panel

Martin S. Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, Brian Conway, Daniel R. Kuritzkes, Richard T. D'Aquila, Lisa M. Demeter, Scott M. Hammer, Victoria A. Johnson, Clive Loveday, John W. Mellors, Donna M. Jacobsen, Douglas D. Richman

Research output: Contribution to journalArticleResearchpeer-review

462 Citations (Scopus)

Abstract

New information about the benefits and limitations of testing for resistance to human immunodeficiency virus (HIV) type 1 (HIV-1) drugs has emerged. The International AIDS Society-USA convened a panel of physicians and scientists with expertise in antiretroviral drug management, HIV-1 drug resistance, and patient care to provide updated recommendations for HIV-1 resistance testing. Published data and presentations at scientific conferences, as well as strength of the evidence, were considered. Properly used resistance testing can improve virological outcome among HIV-infected individuals. Resistance testing is recommended in cases of acute or recent HIV infection, for certain patients who have been infected as long as 2 years or more prior to initiating therapy, in cases of antiretroviral failure, and during pregnancy. Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation.
Original languageEnglish
Pages (from-to)113-128
JournalClinical Infectious Diseases
Volume37
Issue number1
DOIs
Publication statusPublished - 1 Jul 2003

Fingerprint Dive into the research topics of 'Antiretroviral drug resistance testing in adults infected with human immunodefidency virus type 1: 2003 Recommendations of an International Aids Society-USA panel'. Together they form a unique fingerprint.

Cite this